solid tumors – Page 2 – Communicable Diseases Research

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

Article

Published on 2022-08-012022-10-05
Journal: ESMO open [Category] 진단, 치료법,

Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination

간략한 연구 보고서: mRNA 기반 COVID-19 백신 접종을 통한 암 면역 요법에 대한 오래 지속되는 응답자의 항 SARS-CoV-2 면역

Article

Published on 2022-07-052022-09-12
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] analysed antibodies antibody Antibody Response antiviral immune response BNT162b2 Cancer Cancer immunotherapy Cohort Complete Control control group COVID COVID-19 COVID-19 vaccination develop ELISA generate group healthy control IFN-γ IgG titer IgGs immune Immune checkpoint inhibitor immune checkpoint inhibitors (ICIs) immune response Immunotherapy increase in independent induce Long long lasting responders long-lasting median mRNA-based COVID-19 vaccine mRNA-based vaccine mRNA-based vaccines NAb neutralizing antibody neutralizing capacity Patient patients treated prime-boost regimen receiving regimen respond Responder responders responses SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-specific IgG serum antibodies significantly increased solid tumors statistically significant T cell response T cell responses T cells the healthy the patient treated vaccination Vaccine virus
[DOI] 10.3389/fimmu.2022.908108 PMC 바로가기 [Article Type] Article

Natural killer cell homing and trafficking in tissues and tumors: from biology to application

Reviews

Published on 2022-06-292022-10-05
Journal: Signal Transduction and Targeted Therapy [Category] 바이오마커,

Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies

항암치료를 받는 환자의 코로나19 백신접종에 대한 항체 및 T세포 반응

Article

Published on 2022-06-012022-09-11
Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술, 치료제,

[키워드] active treatment adrenal crisis Adrenal insufficiency Affect Anti-CD20 antibodies Anti-CD20 antibody Anti-viral antibodies antibody antibody formation Antibody titer Antibody titers Anticancer therapy B cells B-cell B.1.617.2 blockade Cancer CD4 CD8 Cell cellular Chemoimmunotherapy Chemotherapy Corticosteroids COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination COVID-19 vaccinations COVID-19 vaccine trials cross-reactive cytokine detectable develop dose doses effector cells Endocrine expressed follicular generate healthy donor healthy donors helper cells Humoral response hypoadrenalism Hypothesis IgG antibody titer immune Immunocompromised immunogenic immunogenicity immunogenicity, vaccine Immunotherapy intracellular cytokine staining Lymphocytes mRNA vaccine Multiple myeloma Myeloma n=36 no differences oncology patients Participants Patient Patients with cancer PD-1 peptide peptides Phase 3 profile Prophylactic RBD reactivity receiving Receptor binding domain Safe seronegative seronegative patient Side effect solid tumors spike Spike protein steroid Steroids Stress symptomatic T cell T cell response T cell responses T cells T follicular helper cells T-lymphocytes targeted therapy the SARS-CoV-2 therapy Treatment treatment groups tumors Two patient two patients vaccination Vaccinations Vaccine variant spike was measured were assessed were excluded wild-type WT spike
[DOI] 10.1136/jitc-2022-004766 PMC 바로가기 [Article Type] Article

Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative

백신 접종을 받은 암 환자의 획기적인 COVID-19 감염의 위험과 결과: 국가 COVID 코호트 협력의 실제 증거

Article

Published on 2022-05-012022-09-11
Journal: Journal of clinical oncology : official journal of [Category] COVID19(2023년), SARS, 변종,

[키워드] 95% CI adjusted age analyzed BNT162b2 BNT162b2 vaccine Bone marrow Bone marrow transplantation booster Breakthrough infection breakthrough infections Cancer cancers Cohort controls COVID COVID-19 COVID-19 case COVID-19 cases COVID-19 infection COVID-19 infections Evidence hematologic Hematologic malignancy higher risk identify immunosuppressive effect increased risk leukemia Logistic regression lymphoid lymphoma malignancies medications Moderna mRNA COVID-19 vaccine mRNA COVID-19 vaccines mRNA-1273 Multiple myeloma Myeloma National new SARS-CoV-2 Odds ratios outcome outcomes Patient patients Patients with cancer Pfizer ranged risk SARS-COV-2 infection SARS-CoV-2 variants Sex significantly higher smoking smoking status Solid solid tumors Tumor tumors vaccination Vaccine vaccine dose variants was reduced
[DOI] 10.1200/JCO.21.02419 PMC 바로가기 [Article Type] Article

SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria Findings of a multicentric nationwide study

Original Article

Published on 2022-02-162022-10-29
Journal: Wiener Klinische Wochenschrift [Category] COVID-19, COVID19(2023년), MERS, SARS,

[키워드] acute respiratory syndrome adverse outcomes albumin level association cancer patient cancer treatment Cohort cohort study collected comparable coronavirus coronavirus disease COVID-19 COVID-19 diagnosis diagnosed Diagnosis died disease Factor finding Follow-up General population Hematologic malignancy Hospital admission increased risk independent risk factor investigated Lymphocyte count malignant disease Mortality neutrophil count Older outcome pandemic parameter Patient patients performance status Predictive quarantine Result risk factor Risk factors SARS-CoV-2 SARS-CoV‑2 SARS-CoV‑2 infection SARS-CoV‑2 infection solid tumors Survivors therapy treated Treatment
[DOI] 10.1007/s00508-022-02006-1 PMC 바로가기 [Article Type] Original Article

Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave

심사, 분자 비 인두 면봉 및 빠른 혈청 학적 검사를 포함한 선별 검사 절차를 가진 860 명의 암 환자에서 SARS-COV-2 감염 유병률의 검출.첫 번째 전염병 파의 보고서

Research Article

Published on 2022-02-022022-09-10
Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] adopted anti-cancer therapies anti-SARS-CoV-2 anticancer Asymptomatic Asymptomatic cases balance Cancer cancer patient Cancer patients circulation consecutive patients COVID-19 detect detection diagnostic dose intensity effective Efficacy entity epidemic curve epidemic wave evaluate evaluated feasibility First wave hematologic IgG/IgM antibodies IgM antibodies immunoassay immunologic response Infection Intensive knowledge less lockdown measure Measures molecular Nasopharyngeal swab neoplastic NPs Outpatient Patient patient population performed positive Prevalence primary endpoint questionnaire receiving recommendation reduction SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic screening procedure self-reported symptom Self-reported symptoms serologic test serological serological test Serological tests solid tumors Symptom tested the epidemic the patient the SARS-CoV-2 therapy Triage tumors vaccination weapon
[DOI] 10.1371/journal.pone.0262784 PMC 바로가기 [Article Type] Research Article

COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety

Article

Published on 2022-01-212022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] Administered Admission age anticancer BNT162b2 Cancer cancer patient Cancer patients clinical trial Comorbidity composed conditions conducted control group control groups coronavirus disease COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines death Department effective evaluate excluded Factor female patient healthy volunteer healthy volunteers hematological hematology high risk IgG titer institution intensive care intubation Italy median mRNA1273 North Old patients Older older patient Patient Patients with cancer Post-vaccine primary endpoint Rate reported Risk factors Safe Safety SARS-CoV-2 secondary endpoint Secondary endpoints Seroconversion Side effect significantly lower solid tumor solid tumors the patient Treatment two-dose regimen vaccination Vaccine Year
[DOI] 10.3390/vaccines10020164 PMC 바로가기 [Article Type] Article

A Systematic Review Assessing the Underrepresentation of Cancer Patients in COVID-19 Trials

Article

Published on 2022-01-012022-11-15
Journal: Acta haematologica [Category] SARS, 진단,

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

암 환자의 세로 SARS-CoV-2 mRNA 백신 유도 체액 면역 반응

Article

Published on 2021-12-152022-09-11
Journal: Cancer research [Category] MERS, SARS, 진단, 치료법,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike antibody antibody levels Antibody Response B-cell BNT162b2 booster booster vaccination booster vaccinations Breakthrough infection breakthrough infections Cancer clinical care coronavirus COVID-19 illness dose elicit evaluated Follow-up Frequency hematologic humoral responses Immune checkpoint inhibitor Immune checkpoint inhibitors immune responses immunogenicity Immunoglobulin implication longitudinal Longitudinal studies malignancies median mRNA mRNA-1273 Patient patient selection patients Patients with cancer peak levels Population prospective cohort study receiving reduced remained respiratory response SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines sequence severe acute respiratory syndrome Coronavirus severe COVID-19 illness Solid solid tumor solid tumors sustained therapeutic trajectory Treatment Tumor tumors vaccination Vaccinations Vaccine vaccine-induced immune response Variation
[DOI] 10.1158/0008-5472.CAN-21-3554 PMC 바로가기 [Article Type] Article